Related Experiment Videos

The Future of Radioligand Therapy: α, β, or Both?

Uwe Haberkorn^1,2, Frederik Giesel³, Alfred Morgenstern⁴

¹Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany uwe.haberkorn@med.uni-heidelberg.de.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine

|April 15, 2017

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Evaluation of the biodistribution of [99mTc]Tc-PSMA-GCK01 SPECT/CT in a prospective, intraindividual comparison with [68Ga]PSMA-11 PET/CT for phenotyping in mCRPC prior to PSMA-targeted radioligand therapy.

EJNMMI research·2026

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation.

Frontiers in oncology·2026

Inline gamma spectroscopy and liquid scintillation HPLC reveal daughters in 225Ac-radiopharmaceutical.

EJNMMI radiopharmacy and chemistry·2026

Predicting tumour and organ dose in α-radiopharmaceutical therapy: a 89Zr-based dosimetric approach for 225Ac.

European journal of nuclear medicine and molecular imaging·2026

Chelator-Free Radiometal Labeling Inside Engineered Affibodies.

Angewandte Chemie (International ed. in English)·2026

MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE Trial.

European urology oncology·2026

See all related articles